Fipaxalparant

N/A

Report date: 2026/03/21 20:00:21
NME

Base Information

Drug NameFipaxalparant
Drug Alias NameSAR-100842HZN-825CZN-001A003423457AMG-670
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysophosphatidic acid receptor Edg-7 antagonistsLysophosphatidic acid receptor Edg-2 antagonists
TargetsLysophosphatidic acid receptor Edg-7Lysophosphatidic acid receptor Edg-2
Therapy Area/IndicationsScleroderma, DiffuseScleroderma, SystemicIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[23
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsScleroderma, DiffuseScleroderma, SystemicIdiopathic Pulmonary Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A